NewsDetails

Rachel Darwin, Senior Manager, Public Relations Free information from the National Comprehensive Cancer Network offers information on how and why to access genetic counseling and testing for multiple hereditary cancers. PLYMOUTH MEETING, PA [January 16, 2025] — Today, the National Comprehensive Cancer Network ® (NCCN ®) — an alliance of leading cancer centers — published a new resource to inform people about the latest recommendations around hereditary and familial cancer risk. This essential guide is

Read the full article here

Source: www.nccn.org

Categories: Oncologists1, General Medicine News

Tweets with this article

National Comprehensive Cancer Network (NCCN)

New NCCN Patient Resource Shares Latest Understanding of Genetic Testing to Guide Patient Decision Making. Learn more: https://t.co/mEoHbmxSYo https://t.co/x4KmREBv7j

Related Articles

New Research Shows Inherited Genetic Variants Increase Risk of Certain Pediatric Cancers

A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.

OncLive.com January 21, 2025

IMMagine-1: Preliminary phase II results of anitocabtagene autoleucel in patients with triple-class exposed RRMM

We summarize key preliminary results from the phase II IMMagine-1 study investigating the efficacy and safety of the BCMA-directed CAR T-cell therapy anitocabtagene autoleucel in…

Multiple Myeloma Hub January 21, 2025

Deep phenotyping of nodal T-cell lymphomas reveals immune alterations and therapeutic targets

Whereas immunotherapies have revolutionized the treatment of different solid and hematologic cancers, their efficacy in nodal peripheral T-cell lymphomas (PTCL) is limited, due to a…

Haematologica January 21, 2025

ALLG trial: Ibrutinib plus R-mini-CHOP in older patients with newly diagnosed DLBCL

We summarize key results from the phase II ALLG study of ibrutinib + R-mini-CHOP in older patients with newly diagnosed DLBCL.

Lymphoma Hub January 21, 2025

Insights into mRNA expression in ADC targets in metastatic breast cancer

Kristien Borremans, PhD, KU Leuven, Louvain, Belgium, discusses findings from the UPTIDER trial (NCT04531696), which analyzed the mRNA expression of 72 antibody-drug conjugate (ADC) targets…

VJ Oncology January 21, 2025

Advances in precision medicine for breast cancer in 2025

Jenna Canzoniero, MD, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD, provides an overview of recent advancements in precision medicine for breast cancer, emphasizing the…

VJ Oncology January 21, 2025

FDA approves acalabrutinib with bendamustine and rituximab for previously untreated MCL

On January 16, 2025, the U.S. Food and Drug Administration (FDA) approved acalabrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with bendamustine and rituximab…

VJHemOnc January 21, 2025

World Cancer Day 2025: International Journal of Cancer

The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.

International Journal of Cancer January 21, 2025

Trump orders US to leave World Health Organization

Trump has long been critical of how the Geneva-based institution handled the Covid-19 pandemic.

The Lancet Oncology January 21, 2025

Zolbetuximab Plus Chemo Wins Approval in China for CLDN18.2+ Advanced Gastric/GEJ Adenocarcinoma

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

OncLive.com January 21, 2025